Author:
Becker Timothy D.,Eschliman Evan L.,Thakrar Ashish P.,Yang Lawrence H.
Abstract
Stigma toward people taking medication for opioid use disorder (MOUD) is prevalent, harmful to the health and well-being of this population, and impedes MOUD treatment resource provision, help-seeking, and engagement in care. In recent years, clinicians have implemented new models of MOUD-based treatment in parts of the United States that integrate buprenorphine initiation into emergency departments and other acute general medical settings, with post-discharge linkage to office-based treatment. These service models increase access to MOUD and they have potential to mitigate stigma toward opioid use and MOUD. However, the empirical literature connecting these emerging service delivery models to stigma outcomes remains underdeveloped. This paper aims to bridge the stigma and health service literatures via a conceptual model delineating how elements of emerging MOUD service models can reduce stigma and increase behavior in pursuit of life goals. Specifically, we outline how new approaches to three key processes can counter structural, public, and self-stigma for this population: (1) community outreach with peer-to-peer influence, (2) clinical evaluation and induction of MOUD in acute care settings, and (3) transition to outpatient maintenance care and early recovery. Emerging service models that target these three processes can, in turn, foster patient empowerment and pursuit of life goals. There is great potential to increase the well-being of people who use opioids by reducing stigma against MOUD via these structural changes.
Subject
Psychiatry and Mental health
Reference95 articles.
1. Leading causes of death in the US during the COVID-19 pandemic, march 2020 to October 2021;Shiels;JAMA Intern Med,2022
2. Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on drug use and healthRockville, MD2019
3. The ASAM National Practice Guideline for the treatment of opioid use disorder: 2020 focused update;Cunningham,2020
4. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence;Mattick;Cochrane Database Syst Rev,2014
5. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved;Degenhardt;Drug Alcohol Depend Depend,2009